Promising early efficacy data in LIBRETTO-001 alongside the efficacy data demonstrated in the 343 patients with RET fusion-positive NSCLC and thyroid cancer enrolled in the same trial allowed the drug to gain the accelerated FDA approval designation. The gene discussed is RET; the disease is thyroid gland carcinoma.